{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:39:26Z","timestamp":1765805966402,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004299","name":"SENESCYT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004299","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.drudis.2020.02.008","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T11:33:38Z","timestamp":1583148818000},"page":"1043-1053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Acyclic nucleoside phosphonates as possible chemotherapeutics against Trypanosoma brucei"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-7420","authenticated-orcid":false,"given":"David","family":"Ter\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2020.02.008_bib0005","first-page":"1","article-title":"Control and surveillance of human African trypanosomiasis","volume":"984","author":"WHO","year":"2013","journal-title":"World Health Organ. Tech. Rep. Ser."},{"year":"2015","series-title":"Health in 2015: from MDGs, Millennium Development Goals to SDGs, Sustainable Development Goals","author":"WHO","key":"10.1016\/j.drudis.2020.02.008_bib0010"},{"key":"10.1016\/j.drudis.2020.02.008_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1741-7015-8-67","article-title":"Control of neglected tropical diseases needs a long-term commitment","volume":"8","author":"Zhang","year":"2010","journal-title":"BMC Med."},{"key":"10.1016\/j.drudis.2020.02.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001007","article-title":"The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000\u20132009: the way forward","volume":"5","author":"Simarro","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"year":"2015","series-title":"Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected diseases 2015","author":"WHO","key":"10.1016\/j.drudis.2020.02.008_bib0025"},{"key":"10.1016\/j.drudis.2020.02.008_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001859","article-title":"Estimating and mapping the population at risk of sleeping sickness","volume":"6","author":"Simarro","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2020.02.008_bib0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.actatropica.2015.06.003","article-title":"Human African trypanosomiasis prevention, treatment and control costs: a systematic review","volume":"150","author":"Keating","year":"2015","journal-title":"Acta Trop."},{"key":"10.1016\/j.drudis.2020.02.008_bib0040","first-page":"257","article-title":"Epidemiology of human African trypanosomiasis","volume":"6","author":"Franco","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0045","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1469-0691.2011.03536.x","article-title":"Sleeping sickness","volume":"17","author":"Malvy","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.drudis.2020.02.008_bib0050","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.pt.2003.09.002","article-title":"Chemotherapy of human African trypanosomiasis: current and future prospects","volume":"19","author":"Fairlamb","year":"2003","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2015.00032","article-title":"Transport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma brucei","volume":"6","author":"Munday","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpddr.2015.04.002","article-title":"Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates","volume":"5","author":"Graf","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.drudis.2020.02.008_bib0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijpddr.2013.12.001","article-title":"Trypanosoma brucei adenine-phosphoribosyltransferases mediate adenine salvage and aminopurinol susceptibility but not adenine toxicity","volume":"4","author":"L\u00fcscher","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.drudis.2020.02.008_bib0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1087057114550585","article-title":"Chagas disease drug discovery: toward a new era","volume":"20","author":"Chatelain","year":"2014","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.drudis.2020.02.008_bib0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1590\/S0074-02762007000900018","article-title":"Chagas disease: what is known and what is needed-A background article","volume":"102","author":"Coura","year":"2007","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.drudis.2020.02.008_bib0085","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00436-013-3398-z","article-title":"P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance","volume":"112","author":"Oliviera","year":"2013","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.drudis.2020.02.008_bib0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/jmbi.1994.0137","article-title":"The crystal structure of cruzain: a therapeutic target for Chagas\u2019 disease","volume":"247","author":"McGrath","year":"1995","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1590\/S0074-02762009000900034","article-title":"Two approaches to discovering and developing new drugs for Chagas disease","volume":"104","author":"McKerrow","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.drudis.2020.02.008_bib0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/14728220802623881","article-title":"Trypanosoma cruzi targets for new chemotherapeutic approaches","volume":"13","author":"Soeiro","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.drudis.2020.02.008_bib0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/157489107779561625","article-title":"An insight on targets and patented drugs for chemotherapy of Chagas disease","volume":"2","author":"Duschak","year":"2007","journal-title":"Recent Pat. Antiinfect. Drug Discov."},{"key":"10.1016\/j.drudis.2020.02.008_bib0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pt.2012.05.005","article-title":"Purine salvage in Leishmania: complex or simple by design?","volume":"28","author":"Boitz","year":"2012","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0115","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2174\/156802611796575911","article-title":"6-oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs","volume":"11","author":"de Jersey","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0120","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1128\/AAC.39.3.620","article-title":"Comparative complement selection in bacteria enables screening for lead compounds targeted to a purine salvage enzyme of parasites","volume":"39","author":"Eakin","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2020.02.008_bib0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1126\/science.1112642","article-title":"The genome of the African trypanosome Trypanosoma brucei","volume":"309","author":"Berriman","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.drudis.2020.02.008_bib0130","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1128\/AAC.01787-09","article-title":"Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis","volume":"54","author":"Berg","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2020.02.008_bib0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006301","article-title":"Evaluation of the Trypanosoma brucei 6-oxopurine salvage pathway as a potential target for drug discovery","volume":"12","author":"Dole\u017eelov\u00e1","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2020.02.008_bib0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0166-6851(84)90117-8","article-title":"Purine and pyrimidine metabolism in the Trypanosomatidae","volume":"13","author":"Hammond","year":"1984","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0145","doi-asserted-by":"crossref","DOI":"10.1038\/srep35894","article-title":"Crystal structures and inhibition of Trypanosoma brucei hypoxanthine-guanine phosphoribosyltransferase","volume":"6","author":"Ter\u00e1n","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2020.02.008_bib0150","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1111\/febs.14987","article-title":"Crystal structures of Trypanosoma brucei hypoxanthine\u2013guanine\u2013xanthine phosphoribosyltransferase in complex with IMP, GMP and XMP","author":"Ter\u00e1n","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.drudis.2020.02.008_bib0155","doi-asserted-by":"crossref","first-page":"20231","DOI":"10.1074\/jbc.R000002200","article-title":"Purine phosphoribosyltransferases","volume":"275","author":"Craig","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0160","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.2174\/092986710791556023","article-title":"Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy?","volume":"17","author":"Berg","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0165","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jmb.2005.05.061","article-title":"The crystal structure of free human hypoxanthine-guanine phosphoribosyltransferase reveals extensive conformational plasticity throughout the catalytic cycle","volume":"351","author":"Keough","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0170","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.1021\/bi990664p","article-title":"The 2.0 \u00c5 structure of malarial purine phosphoribosyltransferase in complex with a transition-state analogue inhibitor","volume":"38","author":"Shi","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2020.02.008_bib0175","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1110\/ps.0201002","article-title":"Crystal structures of free, IMP-, and GMP-bound Escherichia coli hypoxanthine phosphoribosyltransferase","volume":"11","author":"Guddat","year":"2002","journal-title":"Protein Sci."},{"key":"10.1016\/j.drudis.2020.02.008_bib0180","doi-asserted-by":"crossref","first-page":"14485","DOI":"10.1021\/bi990507q","article-title":"Crystal structures of the Toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase-GMP and -IMP complexes: comparison of purine binding interactions with the XMP complex","volume":"38","author":"Heroux","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2020.02.008_bib0185","doi-asserted-by":"crossref","first-page":"17120","DOI":"10.1021\/bi9821465","article-title":"Approaching the transition state in the crystal structure of a phosphoribosyltransferase","volume":"37","author":"Focia","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2020.02.008_bib0190","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1128\/AAC.41.8.1686","article-title":"Hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi as a target for structure-based inhibitor design: crystallization and inhibition studies with purine analogs","volume":"41","author":"Eakin","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2020.02.008_bib0195","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1016\/j.bmcl.2004.06.042","article-title":"The purine transferase from Trypanosoma cruzi as a potential target for bisphosphonate-based chemotherapeutic compounds","volume":"14","author":"Fernandez","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2020.02.008_bib0200","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jmb.2003.11.012","article-title":"Interactions at the dimer interface influence the relative efficiencies for purine nucleotide synthesis and pyrophosphorolysis in a phosphoribosyltransferase","volume":"335","author":"Canyuk","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0205","doi-asserted-by":"crossref","first-page":"15066","DOI":"10.1021\/bi981052s","article-title":"A 1.4 \u00c5 crystal structure for the hypoxanthine phosphoribosyltransferase of Trypanosoma cruzi","volume":"37","author":"Focia","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2020.02.008_bib0210","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1021\/acs.jmedchem.5b00611","article-title":"First crystal structures of Mycobacterium tuberculosis 6-oxopurine phosphoribosyltransferase: complexes with GMP and pyrophosphate and with acyclic nucleoside phosphonates whose prodrugs have antituberculosis activity","volume":"58","author":"Eng","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0215","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1021\/jm301893b","article-title":"Acyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of 6-oxopurine phosphoribosyltransferases and have antimalarial activity","volume":"56","author":"Keough","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0220","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/9376","article-title":"The 2.0 \u00c5 structure of human hypoxanthine-guanine phosphoribosyltransferase in complex with a transition-state analog inhibitor","volume":"6","author":"Shi","year":"1999","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0225","doi-asserted-by":"crossref","first-page":"14495","DOI":"10.1021\/bi990508i","article-title":"Crystal structure of Toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase with XMP, pyrophosphate, and two Mg2+ ions bound: insights into the catalytic mechanism","volume":"38","author":"Heroux","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2020.02.008_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6807-7-59","article-title":"Crystal structure of Leishmania tarentolae hypoxanthine-guanine phosphoribosyltransferase","volume":"7","author":"Monzani","year":"2007","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0235","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0092-8674(94)90301-8","article-title":"The crystal structure of human hypoxanthine-guanine phosphoribosyltransferase with bound GMP","volume":"78","author":"Eads","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2020.02.008_bib0240","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.1021\/bi953072p","article-title":"Crystal structure of the hypoxanthine-guanine-xanthine phosphoribosyltransferase from the protozoan parasite Tritrichomonas foetus","volume":"35","author":"Somoza","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2020.02.008_bib0245","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1021\/jm061012j","article-title":"Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases","volume":"49","author":"Keough","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0250","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/med.21283","article-title":"The acyclic nucleoside phosphonates (ANPs): Antonin Holy\u2019s legacy","volume":"33","author":"De Clercq","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.drudis.2020.02.008_bib0255","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/med.21256","article-title":"Highlights in antiviral drug research: antivirals at the horizon","volume":"33","author":"De Clercq","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.drudis.2020.02.008_bib0260","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2020.02.008_bib0265","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1021\/jm900267n","article-title":"Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics","volume":"52","author":"Keough","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0270","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3851\/IMP2012","article-title":"Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy","volume":"22","author":"Pertusati","year":"2012","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.drudis.2020.02.008_bib0275","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.bmc.2011.11.034","article-title":"Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases","volume":"20","author":"Cesnek","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.molbiopara.2010.05.018","article-title":"Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: a target for anti-malarial chemotherapy","volume":"173","author":"Keough","year":"2010","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.drudis.2020.02.008_bib0285","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1021\/jm400779n","article-title":"Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents","volume":"56","author":"Keough","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0290","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bmc.2011.12.034","article-title":"Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents","volume":"20","author":"Krecmerova","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0295","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1021\/jm300662d","article-title":"Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases","volume":"55","author":"Hockova","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0300","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1021\/jm501416t","article-title":"Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agents","volume":"58","author":"Keough","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0305","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1016\/j.bmc.2015.07.038","article-title":"Antimalarial activity of prodrugs of N-branched acyclic nucleoside phosphonate inhibitors of 6-oxopurine phosphoribosyltransferases","volume":"23","author":"Hockova","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2020.02.008_bib0310","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1002\/slct.201601679","article-title":"Crystal structures of acyclic nucleoside phosphonates in complex with Escherichia coli hypoxanthine phosphoribosyltransferase","volume":"1","author":"Eng","year":"2016","journal-title":"ChemistrySelect"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620300787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620300787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:43:24Z","timestamp":1761223404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644620300787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1359644620300787"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2020.02.008","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acyclic nucleoside phosphonates as possible chemotherapeutics against Trypanosoma brucei","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2020.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}